Journal: International Journal of Molecular Sciences
Article Title: Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis
doi: 10.3390/ijms26041778
Figure Lengend Snippet: Class of considered drugs for treating MASH/MASLD.
Article Snippet: , Galectin-3 inhibitor , Belapectin [ , ] , Inhibits galectin-3, targeting fibrosis and inflammation pathways , Large molecule galactoarabino-rhamnogalacturonan polysaccharide inhibitor derived from natural sources; prevents formation of oligomeric structures and lattice-like assemblies that are essential for activating pro-fibrotic signaling pathways, thereby halting fibrosis and reducing liver inflammation.
Techniques: Drug discovery, Control, Clinical Proteomics, Variant Assay, Expressing, Allele-specific Oligonucleotide, Activity Assay, Activation Assay, Derivative Assay, Protein-Protein interactions, Probiotics, Produced, Bacteria, Transplantation Assay